Compare · ABT vs KRRO
ABT vs KRRO
Side-by-side comparison of Abbott Laboratories (ABT) and Korro Bio Inc. (KRRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and KRRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 992.6x KRRO ($176.7M).
- ABT has been more active in the news (12 items in the past 4 weeks vs 7 for KRRO).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Korro Bio Inc.
- Price
- -
- -
- Market cap
- $175.37B
- $176.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest KRRO
- Chief Scientific Officer Vincent Loic A was granted 7,500 shares, increasing direct ownership by 41% to 25,797 units (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver was granted 5,500 shares, increasing direct ownership by 30% to 23,599 units (SEC Form 4)
- General Counsel Cerio Jeffrey was granted 6,500 shares, increasing direct ownership by 18% to 41,793 units (SEC Form 4)
- Chief Operating Officer Chappell Todd was granted 7,500 shares, increasing direct ownership by 44% to 24,464 units (SEC Form 4)
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Formela Jean Francois sold $1,542,970 worth of shares (110,023 units at $14.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Formela Jean Francois sold $2,458,582 worth of shares (171,405 units at $14.34) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)
- General Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)